Small Interfering RNA Market Analysis

Type (Liposome Based Systemic Therapy, Nanoparticle Based Systemic Therapy)

The liposome based systemic therapy segment is estimated to account for 53% share of the global small interfering RNA market during the forecast period. Liposomes offer several advantages as a siRNA delivery system owing to their ability to improve the delivery of antigens and other stimulatory molecules to antigen-presenting cells or T cells. Moreover, liposomes can selectively transport medications to the tumor, can be utilized to deliver specific medications to specific cell types to improve anti-tumor immune responses, and are known to be good carriers for drug delivery in conjunction with other therapies such as chemotherapy, radiation, and phototherapy.

Besides this, clinically proven liposomes are effective against pancreatic cancer as the only liposomal formulation currently licensed for the treatment of metastatic pancreatic cancer is nanoliposomal irinotecan (Onivyde) which was approved by the U.S. Food and Drug Administration (FDA) in 2022.

Indication (Cardiovascular Diseases, Respiratory Diseases, Oncology, Neurodegenerative Diseases, Infectious Diseases)

SiRNA market from the oncology segment is set to garner a notable share of 39% shortly. SiRNA is one of the most essential therapeutic approaches for treating a variety of genetic disorders, including cancer since it has shown promise in the treatment of several malignancies, including breast and prostate cancer. To target cancer, siRNA can be supplied to the entire organism or to a specific tissue which will aid in reducing the expression of various multidrug-resistant genes in cancer cells.

End-User (Hospital, Research Institutions, Pharmaceutical and Biotechnology Companies, Academic Institutions)

The research institutions segment is set to garner significant share of 44% during the forecast timeframe. SiRNA has recently been used in therapeutic applications and is now a potent method for studying gene function in research institutions that can be employed both in vitro and in vivo. Moreover, their use aids in the development of novel techniques to reduce off-target effects brought on by detrimental protein binding or unwanted targeting of mRNA in addition to assist researchers in better understanding the process of gene silence.

Our in-depth analysis of the global market includes the following segments:

Type	Liposome Based Systemic Therapy Nanoparticle Based Systemic Therapy
End-User	Hospital Research Institutions Pharmaceutical and Biotechnology Companies Academic Institutions
Indication	Cardiovascular Diseases Respiratory Diseases Oncology Neurodegenerative Diseases Infectious Diseases

Frequently Asked Questions (FAQ)

Rising cases of cancer across the globe and the growing partnerships and collaborations are the major factors driving the growth of the market.

The market size of small interfering RNA is anticipated to attain a CAGR of 18.5% over the forecast period, i.e., 2024-2036.

The major players in the market are Thermo Scientific, Arbutus Biopharma, Sanofi Genzyme, Sylentis, Arrowhead Research, AInylam Pharmaceuticals, Genecon Biotechnologies, Silent Therapeutics, Horizon Discovery, OPKO Health

The liposome based systemic therapy segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.

Small Interfering RNA Market Analysis